(VIANEWS) – Apollo Medical Holdings (AMEH), Intuitive Surgical (ISRG), Chesapeake Utilities Corporation (CPK) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Apollo Medical Holdings (AMEH)
22.4% sales growth and 9.76% return on equity
Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare management company, provides medical care services. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was founded in 1994 and is headquartered in Alhambra, California.
Earnings Per Share
As for profitability, Apollo Medical Holdings has a trailing twelve months EPS of $1.04.
PE Ratio
Apollo Medical Holdings has a trailing twelve months price to earnings ratio of 37.75. Meaning, the purchaser of the share is investing $37.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.76%.
Yearly Top and Bottom Value
Apollo Medical Holdings’s stock is valued at $39.26 at 19:22 EST, under its 52-week high of $40.81 and way higher than its 52-week low of $28.87.
Volume
Today’s last reported volume for Apollo Medical Holdings is 179669 which is 2.93% below its average volume of 185098.
Moving Average
Apollo Medical Holdings’s worth is higher than its 50-day moving average of $36.57 and way higher than its 200-day moving average of $34.06.
2. Intuitive Surgical (ISRG)
13.7% sales growth and 14.83% return on equity
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
PE Ratio
Intuitive Surgical has a trailing twelve months price to earnings ratio of 77.95. Meaning, the purchaser of the share is investing $77.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.83%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 14.6% and 9.9%, respectively.
Moving Average
Intuitive Surgical’s worth is above its 50-day moving average of $365.82 and way higher than its 200-day moving average of $321.10.
Volume
Today’s last reported volume for Intuitive Surgical is 781551 which is 53.84% below its average volume of 1693310.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.5%, now sitting on 7.12B for the twelve trailing months.
3. Chesapeake Utilities Corporation (CPK)
10.4% sales growth and 8.39% return on equity
Chesapeake Utilities Corporation operates as an energy delivery company. The Regulated Energy segment engages in the natural gas distribution operations in central and southern Delaware, Maryland's eastern shore, and Florida; regulated natural gas transmission in the Delmarva Peninsula and Florida; and regulated electric distribution in northeast and northwest Florida. The Unregulated Energy segment engages in the propane operations in the Mid-Atlantic region and Florida; unregulated natural gas transmission/supply operation in central and eastern Ohio; generation of electricity and steam; and provision of compressed natural gas, liquefied natural gas, and renewable natural gas transportation and pipeline solutions primarily to utilities and pipelines in the eastern United States. This segment also provides other unregulated energy services, such as energy-related merchandise sales; heating, ventilation, and air conditioning services; and plumbing and electrical services. The company was founded in 1859 and is headquartered in Dover, Delaware.
Earnings Per Share
As for profitability, Chesapeake Utilities Corporation has a trailing twelve months EPS of $4.73.
PE Ratio
Chesapeake Utilities Corporation has a trailing twelve months price to earnings ratio of 21.39. Meaning, the purchaser of the share is investing $21.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.39%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Chesapeake Utilities Corporation’s EBITDA is 5.43.
Sales Growth
Chesapeake Utilities Corporation’s sales growth is 21.6% for the current quarter and 10.4% for the next.
4. Incyte Corporation (INCY)
7.6% sales growth and 12.5% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 22.58. Meaning, the purchaser of the share is investing $22.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.5%.
Sales Growth
Incyte Corporation’s sales growth is 8.5% for the present quarter and 7.6% for the next.
Yearly Top and Bottom Value
Incyte Corporation’s stock is valued at $59.85 at 19:22 EST, way below its 52-week high of $76.24 and way above its 52-week low of $50.27.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 135.1% and 18.2%, respectively.
5. Telefonica Brasil, S.A. ADS (VIV)
6.2% sales growth and 7.3% return on equity
Telefônica Brasil S.A., together with its subsidiaries, operates as a mobile telecommunications company in Brazil. Its fixed line services portfolio includes local, domestic long-distance, and international long-distance calls; and mobile portfolio comprises voice and broadband internet access through 3G, 4G, 4.5G, and 5G, as well as mobile value-added and wireless roaming services. The company also offers data services, including broadband and mobile data services. In addition, it provides pay TV services through IPTV technologies; network services, such as rental of facilities; other services comprising internet access, private network connectivity, computer equipment leasing, extended service, caller identification, voice mail, cellular blocker, and others; wholesale services, including interconnection services to users of other network providers; and digital services, such as entertainment, cloud, and security and financial services. Further, the company offers multimedia communication services, which include audio, data, voice and other sounds, images, texts, and other information, as well as sells devices, such as smartphones, broadband USB modems, and other devices. Additionally, it provides telecommunications solutions and IT support to various industries, such as retail, manufacturing, services, financial institutions, government, etc. It markets and sells its solutions through own stores, dealers, retail and distribution channels, door-to-door sales, and outbound tele sales. The company was formerly known as Telecomunicações de São Paulo S.A. – TELESP and changed its name to Telefônica Brasil S.A. in October 2011. The company was incorporated in 1998 and is headquartered in São Paulo, Brazil.
Earnings Per Share
As for profitability, Telefonica Brasil, S.A. ADS has a trailing twelve months EPS of $0.61.
PE Ratio
Telefonica Brasil, S.A. ADS has a trailing twelve months price to earnings ratio of 17.8. Meaning, the purchaser of the share is investing $17.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.3%.
Moving Average
Telefonica Brasil, S.A. ADS’s worth is above its 50-day moving average of $10.64 and way above its 200-day moving average of $9.49.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Dec 27, 2023, the estimated forward annual dividend rate is 0.59 and the estimated forward annual dividend yield is 5.42%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Telefonica Brasil, S.A. ADS’s EBITDA is 3.97.
